Does perioperative FLOT increase cure rates in resectable esophageal adenocarcinoma? A mixture cure model analysis


Por: Mateos, L, Jiménez-Fonseca, P, Gallego, J, Lecumberri, A, Custodio, A, de Castro, EM, San Gil, RH, Montes, AF, Limon, ML, Vidal-Tocino, R, Cano, JM, Robles, JL, Gil, M, Eyzaguirre, DA, Zafra, GM, Mérida-García, AJ, Fernández, AF, Fernández, PR, Hierro, C, Riesco, MC, Araque, MG, Martín, MR, Pimentel, P, Visa, L, Cerdá, P, Granja, M, Blanco, ABR, Gutiérrez, L and Carmona-Bayonas, A

Publicada: 8 feb 2026 Ahead of Print: 1 nov 2025
Resumen:
BackgroundTranslating trial findings to real-world cure rates for resectable oesophageal and gastroesophageal junction (GEJ) adenocarcinoma is critical. Standard endpoints like disease-free survival (DFS) may not distinguish durable cures from delayed recurrences.MethodsThis analysis of the AGAMENON-SEOM registry (NCT04958720) compared perioperative chemotherapy versus neoadjuvant chemoradiotherapy (nCRT). We estimated cure rates and analysed DFS and overall survival (OS) using mixture cure models and Cox proportional hazards models.ResultsIn 500 patients, perioperative FLOT improved DFS (HR 0.60; p = 0.01) and OS (adjusted HR 0.63; p = 0.015) compared to CROSS-based nCRT. Notably, cure models confirmed a higher cure fraction for FLOT in high-risk subgroups (e.g., stage III, high neutrophil-to-lymphocyte ratio). While platinum-fluoropyrimidine-based nCRT +/- immunotherapy yielded higher R0 and pathological complete response rates, its estimated cure rate was comparable to FLOT, both overall and across all subgroups.ConclusionCure is an informative endpoint in localised oesophageal cancer. In this registry analysis, perioperative FLOT was associated with higher cure rates than CROSS, particularly in high-risk subgroups. Exploratory findings suggest that alternative neoadjuvant strategies, such as those incorporating ICIs or FOLFOX, warrant further investigation.

Filiaciones:
Mateos, L:
 Hosp Univ Cent Asturias HUCA, Dept Med Oncol, ISPA, Oviedo, Spain

 Univ Valladolid, Valladolid, Spain

Jiménez-Fonseca, P:
 Hosp Univ Cent Asturias HUCA, Dept Med Oncol, ISPA, Oviedo, Spain

Gallego, J:
 Hosp Gen Univ Elche, Dept Med Oncol, Elche, Spain

Lecumberri, A:
 Hosp Univ Navarra, Dept Med Oncol, Navarrabiomed Inst Invest Sanitaria Navarra IdiSNA, Pamplona, Spain

Custodio, A:
 Hosp Univ La Paz, Dept Med Oncol, CIBERONC CB16-12-00398, Madrid, Spain

de Castro, EM:
 Hosp Univ Marques Valdecilla, Dept Med Oncol, IDIVAL, Santander, Spain

San Gil, RH:
 Hosp Univ Canarias, Dept Med Oncol, San Cristobal la Laguna, Tenerife, Spain

Montes, AF:
 Complejo Hosp Univ Ourense, Dept Med Oncol, Orense, Spain

Limon, ML:
 Hosp Univ Virgen Rocio, Dept Med Oncol, Seville, Spain

Vidal-Tocino, R:
 Complejo Asistencial Univ Salamanca IBSAL, Dept Med Oncol, Salamanca, Spain

Cano, JM:
 Hosp Gen Univ Ciudad Real, Dept Med Oncol, Ciudad Real, Spain

Robles, JL:
 Univ Murcia, Hosp Univ Morales Meseguer, Dept Med Oncol, IMIB, Murcia, Spain

Gil, M:
 Hosp Clin Univ Valencia, Dept Med Oncol, CIBERONC CB16-12-0035, Valencia, Spain

Eyzaguirre, DA:
 Hosp Univ Vall dHebron, Dept Med Oncol, VHIO, Barcelona, Spain

Zafra, GM:
 Hosp Univ Virgen Arrixaca, Dept Med Oncol, Murcia, Spain

Mérida-García, AJ:
 Complejo Asistencial Zamora, Dept Med Oncol, Zamora, Spain

Fernández, AF:
 Complejo Hosp Univ Pontevedra, Dept Med Oncol, Pontevedra, Spain

Fernández, PR:
 Hosp Univ Parc Tauli, Inst Recerca & Innovacio Parc Tauli I3PT CERCA, Dept Med Oncol, Sabadell, Spain

:
 Inst Catala Oncol ICO Badalona, Dept Med Oncol, Badalona Appl Res Grp Oncol B ARGO, Badalona, Spain

Riesco, MC:
 Hosp Univ 12 Octubre, Dept Med Oncol, IMAS12, Madrid, Spain

Araque, MG:
 Hosp Gen Univ Alicante, Dept Med Oncol, Alicante, Spain

Martín, MR:
 Complejo Asistencial Univ Palencia, Dept Med Oncol, Palencia, Spain

Pimentel, P:
 Hosp Univ Santa Lucia, Dept Med Oncol, Cartagena, Spain

Visa, L:
 Hosp El Mar, Dept Med Oncol, Barcelona, Spain

Cerdá, P:
 Hosp Santa Creu I St Pau, Dept Med Oncol, Barcelona, Spain

Granja, M:
 Hosp Univ Clin San Carlos, Dept Med Oncol, Madrid, Spain

Blanco, ABR:
 Hosp Univ Toledo, Dept Med Oncol, Toledo, Spain

Gutiérrez, L:
 Hosp Univ Puerta Hierro, Dept Med Oncol, Madrid, Spain

Carmona-Bayonas, A:
 Univ Murcia, Hosp Univ Morales Meseguer, Dept Med Oncol, IMIB, Murcia, Spain
ISSN: 00070920





British Journal of Cancer
Editorial
Nature Publishing Group, CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 134 Número: 3
Páginas: 414-427
WOS Id: 001624707600001
ID de PubMed: 41298815
imagen Green Submitted, hybrid

MÉTRICAS